GOeVisit Assets Sold
Aja Health and Wellness Inc. Announces Agreement to Sell GOeVisit Service Assets
Anonymous
Aja Health and Wellness Inc. has agreed to sell the core assets of its GOeVisit telehealth service for $1,150,000 CAD, according to Financial Post. The buyer is Health Care Services International Inc., operating as Novus Health — a Canadian health navigation company. The deal closed on June 1, 2026, just days before the public announcement.
The sale marks a sharp strategic turn for Aja, a TSX Venture Exchange company trading under the symbol "AJA." The company is now pivoting away from virtual care and toward natural health products, National Post reported. Assets sold include GOeVisit's technology and related intellectual property.
What Aja Is Selling and Who Is Buying
GOeVisit is a Canadian telehealth platform that connects patients with doctors online. It covers more than 450 minor illnesses, according to Cochrane Times Post. The platform was Aja's flagship product and the main reason the company existed in its current form after a 2024 corporate restructuring.
Novus Health, the buyer, is positioning the deal as a way to add virtual primary care to its existing health navigation services. CEO Jamie Marcellus said the acquisition "represents an important step in the continued evolution of Novus Health's healthcare assistance platform," according to Northern News. For Novus, this means skipping years of building technology from scratch.
FDA Warning and a Messy Road to the Sale
The timing of the sale raised eyebrows. Just 17 days before the deal closed, the U.S. Food and Drug Administration sent a formal warning letter to Aja's CEO, Sanjeev Parsad. The FDA flagged Aja's "Aja Migraine Relief" nasal sprays as unapproved drugs being sold illegally in the United States, according to Owen Sound Sun Times.
Aja also faced a Management Cease Trade Order in May 2025. Canadian regulators issued it because the company was late filing its 2024 financial statements. Auditors struggled with how to classify a complex 2024 reverse takeover — a deal where a private company goes public by merging with a shell company — according to Fort Saskatchewan Record. The stock has sat near $0.035 CAD per share in recent weeks.
$1.15 Million Sale Price Looks Low Against Prior Valuations
Independent valuators placed Aja's equity between $2.87 million and $3.64 million CAD as recently as mid-2024. Selling its primary asset for $1.15 million suggests the company accepted a significant discount. The gap between the sale price and those earlier estimates runs as high as $2.49 million, according to documents filed on SEDAR+, Canada's public securities database.
Aja CEO Sanjeev Parsad framed the deal differently. He said it "supports Aja's strategic priorities for the future" and will help GOeVisit grow under new ownership, according to Sault This Week. Whether the $1.15 million is enough to fund Aja's next chapter — and cover any costs tied to the FDA response — remains unclear.
What Happens Next for GOeVisit Users and Aja
GOeVisit patients across Canada are expected to move into the Novus Health ecosystem. Marcellus said the goal is to build "connected healthcare experiences" that go beyond simple video calls, according to Goderich Signal Star. Aja had recently signed a broker deal with Greatway Financial to market a GOeVisit-linked wellness program nationwide, meaning thousands of Canadians may be affected by the transition.
Aja itself is now focused on its natural health products division, specifically flavonoid-based treatments developed under its Aja Therapeutics brand. But with an active FDA warning letter requiring a response within 15 business days, and a stock price near rock bottom, the company faces real pressure to prove its new direction can work, according to Fort McMurray Today.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
18
Reach
19
A
AnonymousAuthor
